Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131
about
Human IgG4: a structural perspectiveA perspective on the structure and receptor binding properties of immunoglobulin G FcAdvances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-lifeStructure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding.Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement.Mouse and human FcR effector functions.Structural mechanism of high affinity FcγRI recognition of immunoglobulin G.Structural analysis of Fc/FcγR complexes: a blueprint for antibody design.Harnessing co-stimulatory TNF receptors for cancer immunotherapy: Current approaches and future opportunities.Role of Fc-FcγR interactions in the antitumor activity of therapeutic antibodies.IgG Fc variant cross-reactivity between human and rhesus macaque FcγRs.Glycosylation of IgG-Fc: a molecular perspective.Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI.Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.Optimization of protein-protein docking for predicting Fc-protein interactions.Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody.Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization.Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?Inhibitory FcγRIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc Engineering.Enrichment of high affinity subclasses and glycoforms from serum-derived IgG using FcγRs as affinity ligands.IgG Fc engineering to modulate antibody effector functions.FcγRII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody.
P2860
Q26779758-BEDE26A3-C744-449C-85F1-B1240953CB1EQ26827579-109BAF4F-16A1-4B2B-A4ED-51D3C5E60AC2Q28079016-543678C3-5AD6-49EF-8C28-E909F77A30ABQ35031336-A1E9FD4D-1771-4104-ACA4-516D6C6E9D24Q35569901-5F4B2DB3-A722-4E73-A635-794BA49F946DQ36624176-FBACBB3F-2B4C-4DCD-86D5-5A3BA4833EA0Q37114367-B3F9AFCB-622C-4029-B6C6-EAB80C3C50B6Q37155745-B5639B87-3C35-4589-9D36-44F1C08BB6FBQ38615349-8F0FE6CF-8F35-4E54-9D24-8CA9450D6A7BQ38615372-50CD28F3-4837-472A-9125-19C68E1F7365Q38615376-46B8B0E6-7CC8-4ACE-8E5E-599FA20B5C1BQ38770814-447F7A13-0891-4E42-9A74-19A0E4516D45Q38782706-D3443E27-B125-49C8-BCF2-7755321F14FBQ39038535-811F7397-B2AC-460E-8948-7646E23F199DQ39401108-3CBA1167-42AE-47B2-A84D-7633A9F1E46EQ40388373-9659F18A-318E-493A-B399-E31780893FEFQ40560816-B1E30D35-5CB4-40F9-95E2-316A405B4509Q40604291-1D12515D-CF87-4A7D-8F66-37C5B3EBEBEBQ41104888-FEB608E4-2344-45EF-8E5F-0EF5C38A829FQ42280832-2C08FEBC-47C3-4178-881D-EB0E54B870B9Q42372842-6ADAFBEC-47E0-460F-BE7B-508BB6972865Q42584647-95C79978-5188-4ACB-AE47-F66016BE6C5FQ47190029-A077C670-3D47-496A-8994-19886ABA1F86Q47593242-BECD0106-4204-4A34-B719-8FEDF14281B6Q49847008-2F84A492-4043-44FE-92F8-046926CBEEC5
P2860
Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Engineered antibody Fc variant ...... th Fc RIIaR131 and Fc RIIaH131
@ast
Engineered antibody Fc variant ...... th Fc RIIaR131 and Fc RIIaH131
@en
Engineered antibody Fc variant ...... th Fc RIIaR131 and Fc RIIaH131
@nl
type
label
Engineered antibody Fc variant ...... th Fc RIIaR131 and Fc RIIaH131
@ast
Engineered antibody Fc variant ...... th Fc RIIaR131 and Fc RIIaH131
@en
Engineered antibody Fc variant ...... th Fc RIIaR131 and Fc RIIaH131
@nl
prefLabel
Engineered antibody Fc variant ...... th Fc RIIaR131 and Fc RIIaH131
@ast
Engineered antibody Fc variant ...... th Fc RIIaR131 and Fc RIIaH131
@en
Engineered antibody Fc variant ...... th Fc RIIaR131 and Fc RIIaH131
@nl
P2093
P2860
P356
P1476
Engineered antibody Fc variant ...... cγRIIa(R131) and FcγRIIa(H131)
@en
P2093
T Kuramochi
T Miyazaki
P2860
P304
P356
10.1093/PROTEIN/GZT022
P50
P577
2013-06-05T00:00:00Z